Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mutation Profile Detection, Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy of Advanced NSCLC Patients in China

NCT03059641 is registered in ClinicalTrials.gov with Geneplus-Beijing Co. Ltd. as lead sponsor.

NCT NCT03059641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03059641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mutation Profile Detection, Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy of Advanced NSCLC Patients in China
Lead sponsor
Geneplus-Beijing Co. Ltd.
Phase
Observational
Overall status
Completed
Start date
February 22, 2017
Completion date
January 30, 2020
Enrollment
300 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung, lung cancer, nonsmall cell, lung neoplasms, squamous cell lung cancer